Abstract:The prognosis of refractory/relapsed (R/R) acute lymphoblastic leukemia (ALL) is poor with chemotherapy or even allogeneic hematopoietic stem cell transplantation (HSCT). Although CD19 targeted chimeric antigen receptor T cells (CART19) have resulted in 90% complete remission (CR) in R/R ALL, many patients will eventually relapse. Haploidentical HSCT appears to be a promising strategy for patients with R/R ALL, with a theoretically high donor availability of almost 100%, as well as being less time-consuming than conventional HSCT. Moreover, haploidentical HSCT could trigger a more potent graft versus leukemia effect compared with HLA-identical transplants, which might facilitate the repression of leukemia relapse. However, relapsing hematologic malignancies after haploidentical HSCT still remains the most common cause of death. Here we sought to determine the safety and efficacy of CART19 therapy followed by haploidentical HSCT for R/R ALL patients. 11 patients with R/R ALL underwent CART19 therapy followed by haploidentical HSCT from December 2016 to July 2017 in the current study. Disease status before haploidentical HSCT was 27.3% cases in CR1 and 45.5% in CR2 while 27.3% relapsed after CART19 therapy and underwent salvage haploidentical HSCT. For patients in CR, 75.0% cases were MRD<.01% but with elevated normal CD19+ B cells. Consequently, no patients died of transplant-associated complications. The median time to neutrophil and platelet engraftment were 14.3 and 15.8 days compared with 12.0 and 15.0 days in our previous report respectively (P > .05). Cumulative incidence of grade II-IV acute GVHD (aGVHD) was 45.5% compared with 42.2% in our previous report (P > .05). With a median follow-up of 9.8 months post haploidentical HSCT, 5 patients (45.5%) relapsed who were MRD positive before HSCT. The relapse rates between patients with MRD negative and patients with MRD positive were statistically different (0% versus 45.5%, P < .01). In conclusion, our study showed that MRD<.01% before transplantation was strongly related with low incidence of relapse. Haploidentical HSCT can greatly improve the overall clinical outcomes in R/R ALL patients after CART19 therapy.

CD19 Targeted CAR-T Therapy Followed by Haploidentical HSCT for Refractory/Relapsed Acute Leukemia: Superior Therapeutic Efficacy